RT Journal Article
SR Electronic
T1 Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.19.20054262
DO 10.1101/2020.04.19.20054262
A1 Luca Carsana
A1 Aurelio Sonzogni
A1 Ahmed Nasr
A1 Roberta Simona Rossi
A1 Alessandro Pellegrinelli
A1 Pietro Zerbi
A1 Roberto Rech
A1 Riccardo Colombo
A1 Spinello Antinori
A1 Mario Corbellino
A1 Massimo Galli
A1 Emanuele Catena
A1 Antonella Tosoni
A1 Andrea Gianatti
A1 Manuela Nebuloni
YR 2020
UL http://medrxiv.org/content/early/2020/04/22/2020.04.19.20054262.abstract
AB Importance The analysis of lung tissues of patients with COVID-19 may help understand pathogenesis and clinical outcomes in this life-threatening respiratory illness.Objective To determine the histological patterns in lung tissue of patients with severe COVID-19.Design and participants Lungs tissues of 38 cases who died for COVID-19 in two hospital of Northern Italy were systematically analysed. Hematoxylin-eosin staining, immunohistochemistry for the inflammatory infiltrate and cellular components, electron microscopy were performed.Results The features of the exudative and proliferative phases of Diffuse Alveolar Disease (DAD) were found: capillary congestion, necrosis of pneumocytes, hyaline membrane, interstitial oedema, pneumocyte hyperplasia and reactive atypia, platelet-fibrin thrombi. The inflammatory infiltrate was composed by macrophages in alveolar lumens and lymphocytes mainly in the interstice. Electron microscopy revealed viral particles in the cytoplasm of pneumocytes.Conclusions and relevance The predominant pattern of lung lesions in COVID-19 patients is DAD, as described for the other two coronavirus that infect humans, SARS-CoV and MERS-CoV. Hyaline membrane formation and pneumocyte atypical hyperplasia are frequently found. The main relevant finding is the presence of platelet-fibrin thrombi in small arterial vessels; this important observation fits into the clinical context of coagulopathy which dominates in these patients and which is one of the main targets of therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available by the authors.